CRISPR Therapeutics (CRSP) closed at $50.04 on Oct 19, 2026, up 1.6% on the day. The stock is down 11.5% over the past month, up 3.9% over three months, down 4.6% year to date and down 26.9% over the past year. It trades 29.3% below its 52-week high of $70.74 and 13.4% above its 52-week low of $44.12. The close sits below its 50-day moving average ($54.87) and below its 200-day moving average ($53.10).
NextPick tracks CRSP in its Cell / Gene Therapy basket alongside BEAM, VCEL, NTLA, PRME and EDIT. As of Oct 19, 2026, the basket's money-flow score is -18 (weak outflow), and the basket is down 4.8% over five sessions. Over the past month CRSP ranks 6th of 7 basket members by price change.
No — the Oct 19, 2026 close of $50.04 is 5.8% below the 200-day average of $53.10.
CRSP closed 29.3% below its 52-week high of $70.74.
NextPick groups CRSP with BEAM, VCEL, NTLA, PRME and EDIT in its Cell / Gene Therapy basket.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
